These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7997419)

  • 21. Cortical hyperostosis: a complication of prostaglandin E1 treatment in congenital heart disease.
    Smet MH; Marchal G; Lambert L; Devlieger H; Gewillig M
    J Belge Radiol; 1989 Oct; 72(5):377-80. PubMed ID: 2600053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin E1 treatment in ductus dependent congenital cardiac malformation. A review of the treatment of 34 neonates.
    Høst A; Halken S; Kamper J; Lillquist K
    Dan Med Bull; 1988 Feb; 35(1):81-4. PubMed ID: 3342648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin E1 in infants with critical congenital heart disease.
    Dungan WT
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Jan; 1(1):71-4. PubMed ID: 2454319
    [No Abstract]   [Full Text] [Related]  

  • 24. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation.
    Huang FK; Lin CC; Huang TC; Weng KP; Liu PY; Chen YY; Wang HP; Ger LP; Hsieh KS
    Pediatr Neonatol; 2013 Apr; 54(2):102-6. PubMed ID: 23590954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastric-outlet obstruction induced by prostaglandin therapy in neonates.
    Peled N; Dagan O; Babyn P; Silver MM; Barker G; Hellmann J; Scolnik D; Koren G
    N Engl J Med; 1992 Aug; 327(8):505-10. PubMed ID: 1635565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversibility of cortical hyperostosis following long-term prostaglandin E1 therapy in infants with ductus-dependent congenital heart disease.
    Høst A; Halken S; Andersen PE
    Pediatr Radiol; 1988; 18(2):149-53. PubMed ID: 3281113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echocardiographic evaluation of the ductal morphology in patients with refractoriness to lipo-prostaglandin E1 therapy.
    Takeda N; Hiraishi S; Misawa H; Agata Y; Horiguchi Y; Fujino N; Hirota H; Kawamura S; Ogawa N
    Pediatr Int; 2000 Apr; 42(2):134-8. PubMed ID: 10804727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of prostaglandins in duct-dependent congenital heart conditions.
    Singh Y; Mikrou P
    Arch Dis Child Educ Pract Ed; 2018 Jun; 103(3):137-140. PubMed ID: 29162633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of prostaglandins in neonatal cardiology].
    Dinarević S; Kurtagić S; Maksić H
    Med Arh; 2000; 54(5-6):279-82. PubMed ID: 11219904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term variability of heart rate increases with successful closure of patent ductus arteriosus in preterm infants.
    Prietsch V; Maier R; Schmitz L; Obladen M
    Biol Neonate; 1992; 61(3):142-9. PubMed ID: 1610941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologically active levels of PGE1 in neonates with congenital heart disease.
    Leonhardt A; Kühl PG; Schweer H; Wolf D; Seyberth HW
    Acta Paediatr Scand; 1989 Nov; 78(6):853-7. PubMed ID: 2603710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodynamic effects of prostaglandin E1 in patients with congenital heart disease and pulmonary hypertension.
    Weesner KM
    Cathet Cardiovasc Diagn; 1991 Sep; 24(1):10-5. PubMed ID: 1913785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of prostaglandin E1 on the hemodynamics in newborn infants with pulmonary atresia (author's transl)].
    Mocellin R; Sauer U; Schumacher G; Kellner M; Schöber JG
    Z Kardiol; 1978 Aug; 67(8):572-7. PubMed ID: 695809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy.
    Joshi A; Berdon WE; Brudnicki A; LeQuesne G; Ruzal-Shapiro C; Hayes C
    Pediatr Radiol; 2002 Jun; 32(6):405-8. PubMed ID: 12029339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of clinical diagnosis and decision to commence intravenous prostaglandin E1 in neonates presenting with hypoxemia in a transport setting.
    Shivananda S; Kirsh J; Whyte HE; Muthalally K; McNamara PJ
    J Crit Care; 2010 Mar; 25(1):174.e1-9. PubMed ID: 19577418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.
    Kramer HH; Sommer M; Rammos S; Krogmann O
    Eur J Pediatr; 1995 Sep; 154(9):700-7. PubMed ID: 8582419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
    Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
    Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dilation of the ductus arteriosus by oral prostaglandin E1 derivative in cyanotic congenital heart diseases.
    Matsuura H; Saji T; Yamamoto S; Ishikita T; Aoki Y; Matsuo N
    Am Heart J; 1993 May; 125(5 Pt 1):1453-4. PubMed ID: 8480610
    [No Abstract]   [Full Text] [Related]  

  • 40. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.